Street concerns ease as Sun Pharma's specialty segment delivers in Q2
Upsides in the stock will depend on sustaining specialty and India sales growth04-11-2020
04-11-2020
Sun Pharma shares rally over 6 per cent after strong Q2 numbers
Shares of Sun Pharmaceutical Industries continued their rally for the second consecutive day on Wednesday, rising over 6 per cent, after the company r04-11-2020
Earnings Call for Q2FY21 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.03-11-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financials for the second quarter and half year ending September 30th, 2020, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,03-11-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Approval Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2020
The Board of Directors of the Company at its meeting held today i.e. November 03, 2020 has inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2020. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we enclose herewith the following as 'Annexure': a) Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and half year ended September 30, 2020. b) Limited Review Report of the Statutory Auditors of the Company on Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2020. The meeting of the Board of Directors of the Company commenced at 10:30 a.m. and concluded at 02:40 p.m.03-11-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.31-10-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to 5-year sustained efficacy and safety results for ILUMYA(r) in patients with moderate-to-severe plaque psoriasis, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,31-10-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 27, 2020 for Aditya Medisales Ltd27-10-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 27, 2020 for Shanghvi Finance Pvt Ltd27-10-2020
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for loss of share certificate27-10-2020